Idt Australia Limited · ASX:IDT
Idt Australia — H1 FY2026 Earnings Presentation
12 slides from Idt Australia's earnings presentation, Feb 18, 2026
Slide 1: IDT Australia Interim Results FY2026
IDT Australia INTERIM RESULTS FY2026
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not
Slide 3: H1FY26 Result Highlights
H1FY26 Result Highlights Strategic Realignment Under New Leadership Earnings Recovery Operating Revenue Increase A $2.3M increase in EBITDA to a modest loss of Revenue from three verticals (ex low-margin disbursements) $436K & Normalised EBITDA of -$256K (ex one-off jumped 20.3% PCP to $8.4M. redund
Slide 4: Strategic Reset
Strategic Reset Addressing Recent Operational & Financial Challenges Encouraging Early Results Reallocating resources to $9 $1.0 Targeting clients with Millions Millions Ordinary Revenue (LHS) $8.4 opportunities that strongly $0.5 resources & pipeline for EBITDA (RHS) align with IDT’s expertise $8 $
Slide 5: H1FY26 Financial Performance
H1FY26 Financial Performance Returning to Profitability H1FY26 H1FY25 % Chg REVENUE FROM 3 VERTICALS $8.4M $7.0M +20.3% Ordinary revenue growth in the period was driven by API and Specialty Orals businesses Composition: - API 35.4% 14.7% More balanced revenue split between the 3 verticals - Specialt
Slide 6: Cost Optimisation Upgrade
Cost Optimisation Upgrade Doubling in Annualised Cost Savings Target Total Expenses Declined 23% PCP Expected annualised cost savings of $2M (vs. $12 initial target of ~$1M) from FY26. Millions Total Expenses in H1FY26 down 20% PCP to $10 Materials Costs $9.0M, while Operating Expenses dropped 14% P
Slide 7: Performance Breakdown
Performance Breakdown Returning to Profitability Vertical Rev % Chg Comments Interim Revenue Breakdown API $3.0M +191.4% Reestablishing this business as foundation $9 Millions Manufacturing of growth and targeting clients with $8 potential for follow-on contracts to other $7 2 businesses. The strong
Slide 8: Three Business Verticals
Three Business Verticals Re-establishing API Vertical as Foundation for Growth Active Pharmaceutical Ingredient (API) Manufacture • Legacy business and a key strength of IDT • Acts as sales funnel for flow-on work to other 2 verticals to create the finished drug • Development and manufacturing of th
Slide 9: mRNA & Radiopharmaceutical
mRNA & Radiopharmaceutical Key Growth Opportunities First cGMP in-human mRNA vaccine clinical supplier in Australia Leading mRNA vaccine clinical supplier in the southern hemisphere mRNA development partnerships with leading global pharma organisations Global mRNA market forecast to hit US$26.1B by
Slide 10: Further Gains Expected
Further Gains Expected Building on the Early Momentum Positioned for Growth Benefits from Strategic Reset Solid pipeline across all business units Focus on achieving a positive operating profit in the near -term Strongly positioned to capitalise on growing mRNA and Better client targeting for repeat
Slide 11: Board of Directors
Board of Directors Experienced Board and Leadership Team Mark Simari Executive Chair Mark Simari is an experienced and accomplished professional in the health industry and has over 15 years’ Board experience in a diverse range of organisations. Mark was the former managing director and co-founder of
Slide 12: IDT Australia
IDT Australia Investor & Media Enquiries: Brendon Lau e: brendon@vantagepointpartners.com.au m: 0409 341 613